SCI Abstract

search
+
Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995–2022—a Danish nationwide population-based register study
Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995–2022—a Danish nationwide population-based register study
In 2001, the treatment of CML underwent a revolutionary improvement with the...
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801...
The ratio of brain to liver glucose activity and disease activity in multiple myeloma
The ratio of brain to liver glucose activity and disease activity in multiple myeloma
Changes in metabolic activity in tumor cells is one of the hallmarks of cancer. Cancer cells exhibit the Warburg effect wi...
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
The World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of T...
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (R...
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Over-expression of BCL-2 defines follicular lymphoma (FL). Venetoclax (VEN), a selective BCL-2 inhibitor, has previously b...
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
MRD monitoring has increasingly emerged as a pivotal dynamic biomarker in acute myeloid leukemia (AML), offering additiona...
Tumor progression locus 2, a new potential prognostic factor and therapeutic target in activated B-cell-like diffuse large B-cell lymphoma
Tumor progression locus 2, a new potential prognostic factor and therapeutic target in activated B-cell-like diffuse large B-cell lymphoma
Recent developments in categorization based on cell-of-origin (COO) [1] or c...
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Survey of interpretation practices of unbalanced MYC break-apart resultsFifty-four responses were obtained to the survey q...
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Competing interests EM and VG have no conflicts of interest to disclose. S...
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marro...
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Nucleophosmin 1 (NPM1) is one of the most frequently mutated genes (~30% of cases) in acute myeloid l...
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (...
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primari...
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large...
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of tran...
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune...
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort s...
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group
Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine mainly containing Realgar (As4S4), is highly ...
Early mortality after chemotherapy as a quality indicator—the leukemia perspective
Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer pati...
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
Hemodilution of bone marrow (BM) aspirates is a limitation of multiparameter flow cytometry (MFC) in plasma cell disorders...
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
The plasma cell cancer multiple myeloma (MM) varies significantly in genomic characteristics, response to therapy, and lon...
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
T(8;21)(q22;q22.1)/RUNX1::RUNX1T1 is found in 5–10% of all AML cases and responds well to conventional chemotherapy [1]. T...
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple...
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofib...
Correction: TET2 deficiency promotes MDS-associated leukemogenesis
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by abnormal immunogl...
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone wit...
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia
Allogeneic hematopoietic cell transplantation (alloHCT) is an important and curative therapeutic approach...
MRD negativity: considerations for older adults with multiple myeloma
Competing interests HM: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GS...
Load More
format_indent_increase